| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
(Received for publication, April 4, 1997, and in revised form, April 25 1997)
From the Thyroid Molecular Biology Unit, Veterans Administration
Medical Center and the University of California,
San Francisco, California 94121
Previous attempts to generate
autoantibody-reactive, secreted thyrotropin receptor (TSHR)
ectodomain in mammalian cells have failed because of retention within
the cell of material with immature carbohydrate. We have overcome this
difficulty by performing progressive carboxyl-terminal truncations of
the human TSHR ectodomain (418 amino acid residues including signal
peptide). Three ectodomain variants (TSHR-261, TSHR-289, and TSHR-309)
were truncated at residues 261, 289, and 309, respectively. Unlike the
full ectodomain, ectodomain variants were secreted with an efficiency
inversely proportional to their size. Secreted ectodomain variants
contained ~20 kDa of complex carbohydrate. TSHR-261 was chosen for
further study because it was secreted very efficiently and neutralized autoantibodies in Graves' patients' sera. This ectodomain variant was
partially purified using sequential lectin and nickel-chelate chromatography, permitting the first direct visualization and quantitation of the mammalian TSHR. Most important, very small (nanogram) quantities of this material neutralized 70-100% of TSHR
autoantibody activity in all 18 Graves' sera studied.
In summary, carboxyl-terminal truncation of the human TSHR ectodomain
generates a secreted protein with complex carbohydrate that neutralizes
autoantibodies in Graves' patients' sera. Antigenically active
TSHR will be valuable for future studies on the diagnosis, pathogenesis, and immunotherapy of Graves' disease.
Volume 272, Number 30,
Issue of July 25, 1997
pp. 18959-18965
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Mizutori, C.-R. Chen, S. M. McLachlan, and B. Rapoport The Thyrotropin Receptor Hinge Region Is Not Simply a Scaffold for the Leucine-Rich Domain but Contributes to Ligand Binding and Signal Transduction Mol. Endocrinol., May 1, 2008; 22(5): 1171 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. McLachlan, H. A. Aliesky, P. N. Pichurin, C.-R. Chen, R. W. Williams, and B. Rapoport Shared and Unique Susceptibility Genes in a Mouse Model of Graves' Disease Determined in BXH and CXB Recombinant Inbred Mice Endocrinology, April 1, 2008; 149(4): 2001 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. McLachlan, Y. Nagayama, P. N. Pichurin, Y. Mizutori, C.-R. Chen, A. Misharin, H. A. Aliesky, and B. Rapoport The Link between Graves' Disease and Hashimoto's Thyroiditis: A Role for Regulatory T Cells Endocrinology, December 1, 2007; 148(12): 5724 - 5733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-R. Chen, S. M. McLachlan, and B. Rapoport Suppression of Thyrotropin Receptor Constitutive Activity by a Monoclonal Antibody with Inverse Agonist Activity Endocrinology, May 1, 2007; 148(5): 2375 - 2382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. G. Morgenthaler, S. C. Ho, and W. B. Minich Stimulating and Blocking Thyroid-Stimulating Hormone (TSH) Receptor Autoantibodies from Patients with Graves' Disease and Autoimmune Hypothyroidism Have Very Similar Concentration, TSH Receptor Affinity, and Binding Sites J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1058 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Aliesky, P. N. Pichurin, C.-R. Chen, R. W. Williams, B. Rapoport, and S. M. McLachlan Probing the Genetic Basis for Thyrotropin Receptor Antibodies and Hyperthyroidism in Immunized CXB Recombinant Inbred Mice Endocrinology, June 1, 2006; 147(6): 2789 - 2800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Land, P. Gudapati, M. H. Kaplan, and G. S. Seetharamaiah Differential Requirement of Signal Transducer and Activator of Transcription-4 (Stat4) and Stat6 in a Thyrotropin Receptor-289-Adenovirus-Induced Model of Graves' Hyperthyroidism Endocrinology, January 1, 2006; 147(1): 111 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Pichurin, C.-R. Chen, G. D. Chazenbalk, H. Aliesky, N. Pham, B. Rapoport, and S. M. McLachlan Targeted Expression of the Human Thyrotropin Receptor A-Subunit to the Mouse Thyroid: Insight into Overcoming the Lack of Response to A-Subunit Adenovirus Immunization J. Immunol., January 1, 2006; 176(1): 668 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. McLachlan, Y. Nagayama, and B. Rapoport Insight into Graves' Hyperthyroidism from Animal Models Endocr. Rev., October 1, 2005; 26(6): 800 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Pichurin, G. D. Chazenbalk, H. Aliesky, O. Pichurina, B. Rapoport, and S. M. McLachlan "Hijacking" the Thyrotropin Receptor: A Chimeric Receptor-Lysosome Associated Membrane Protein Enhances Deoxyribonucleic Acid Vaccination and Induces Graves' Hyperthyroidism Endocrinology, December 1, 2004; 145(12): 5504 - 5514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-R. Chen, H. Aliesky, P. N. Pichurin, Y. Nagayama, S. M. McLachlan, and B. Rapoport Susceptibility Rather than Resistance to Hyperthyroidism Is Dominant in a Thyrotropin Receptor Adenovirus-Induced Animal Model of Graves' Disease as Revealed by BALB/c-C57BL/6 Hybrid Mice Endocrinology, November 1, 2004; 145(11): 4927 - 4933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ando, R. Latif, S. Daniel, K. Eguchi, and T. F. Davies Dissecting Linear and Conformational Epitopes on the Native Thyrotropin Receptor Endocrinology, November 1, 2004; 145(11): 5185 - 5193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R. Moyle, Y. Xing, W. Lin, D. Cao, R. V. Myers, J. E. Kerrigan, and M. P. Bernard Model of Glycoprotein Hormone Receptor Ligand Binding and Signaling J. Biol. Chem., October 22, 2004; 279(43): 44442 - 44459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Latrofa, G. D. Chazenbalk, P. Pichurin, C.-R. Chen, S. M. McLachlan, and B. Rapoport Affinity-Enrichment of Thyrotropin Receptor Autoantibodies from Graves' Patients and Normal Individuals Provides Insight into Their Properties and Possible Origin from Natural Antibodies J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4734 - 4745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Vassart and S. Costagliola A Physiological Role for the Posttranslational Cleavage of the Thyrotropin Receptor? Endocrinology, January 1, 2004; 145(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
C.-R. Chen, P. Pichurin, G. D. Chazenbalk, H. Aliesky, Y. Nagayama, S. M. McLachlan, and B. Rapoport Low-Dose Immunization with Adenovirus Expressing the Thyroid-Stimulating Hormone Receptor A-Subunit Deviates the Antibody Response toward That of Autoantibodies in Human Graves' Disease Endocrinology, January 1, 2004; 145(1): 228 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Schwarz-Lauer, P. N. Pichurin, C.-R. Chen, Y. Nagayama, C. Paras, J. C. Morris, B. Rapoport, and S. M. McLachlan The Cysteine-Rich Amino Terminus of the Thyrotropin Receptor Is the Immunodominant Linear Antibody Epitope in Mice Immunized Using Naked Deoxyribonucleic Acid or Adenovirus Vectors Endocrinology, May 1, 2003; 144(5): 1718 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nagayama, H. Mizuguchi, T. Hayakawa, M. Niwa, S. M. McLachlan, and B. Rapoport Prevention of Autoantibody-Mediated Graves'-Like Hyperthyroidism in Mice with IL-4, a Th2 Cytokine J. Immunol., April 1, 2003; 170(7): 3522 - 3527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pichurin, O. Pichurina, G. D. Chazenbalk, C. Paras, C.-R. Chen, B. Rapoport, and S. M. McLachlan Immune Deviation Away from Th1 in Interferon-{gamma} Knockout Mice Does Not Enhance TSH Receptor Antibody Production after Naked DNA Vaccination Endocrinology, April 1, 2002; 143(4): 1182 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Cundiff, S. Kaithamana, G. S. Seetharamaiah, J. R. Baker Jr., and B. S. Prabhakar Studies Using Recombinant Fragments of Human TSH Receptor Reveal Apparent Diversity in the Binding Specificities of Antibodies That Block TSH Binding to Its Receptor or Stimulate Thyroid Hormone Production J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4254 - 4260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pichurin, X.-M. Yan, L. Farilla, J. Guo, G. D. Chazenbalk, B. Rapoport, and S. M. McLachlan Naked TSH Receptor DNA Vaccination: A TH1 T Cell Response in Which Interferon-{gamma} Production, Rather than Antibody, Dominates the Immune Response in Mice Endocrinology, August 1, 2001; 142(8): 3530 - 3536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Chazenbalk, S. M. McLachlan, P. Pichurin, X.-M. Yan, and B. Rapoport A Prion-Like Shift between Two Conformational Forms of a Recombinant Thyrotropin Receptor A-Subunit Module: Purification and Stabilization Using Chemical Chaperones of the Form Reactive with Graves' Autoantibodies J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1287 - 1293. [Abstract] [Full Text]
|
|
|
|
|
|
M. H. Lee, J. Y. Park, B. Y. Cho, and C.-B. Chae Expression of the Functional Extracellular Domain of Human Thyrotropin Receptor Using a Vaccinia Virus System: Its Purification and Analysis of Autoantibody Binding J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1391 - 1397. [Abstract] [Full Text]
|
|
|
|
|
|
G. D. Chazenbalk, Y. Wang, J. Guo, J. S. Hutchison, D. Segal, J. C. Jaume, S. M. McLachlan, and B. Rapoport A Mouse Monoclonal Antibody to a Thyrotropin Receptor Ectodomain Variant Provides Insight into the Exquisite Antigenic Conformational Requirement, Epitopes and in Vivo Concentration of Human Autoantibodies J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 702 - 710. [Abstract] [Full Text]
|
|
|
|
|
|
B. Rapoport, G. D. Chazenbalk, J. C. Jaume, and S. M. McLachlan The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies Endocr. Rev., December 1, 1998; 19(6): 673 - 716. [Abstract] [Full Text]
|
|
|
|
|
|
C. R. Da Costa and A. P. Johnstone Production of the Thyrotrophin Receptor Extracellular Domain as a Glycosylphosphatidylinositol-anchored Membrane Protein and Its Interaction with Thyrotrophin and Autoantibodies J. Biol. Chem., May 8, 1998; 273(19): 11874 - 11880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tanaka, G. D. Chazenbalk, S. M. McLachlan, and B. Rapoport Thyrotropin Receptor Cleavage at Site 1 Does Not Involve a Specific Amino Acid Motif but Instead Depends on the Presence of the Unique, 50 Amino Acid Insertion J. Biol. Chem., January 23, 1998; 273(4): 1959 - 1963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-R. Chen, K. Tanaka, G. D. Chazenbalk, S. M. McLachlan, and B. Rapoport A Full Biological Response to Autoantibodies in Graves' Disease Requires a Disulfide-bonded Loop in the Thyrotropin Receptor N Terminus Homologous to a Laminin Epidermal Growth Factor-like Domain J. Biol. Chem., April 27, 2001; 276(18): 14767 - 14772. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
